By Fineline Cube 
Chinese partners Jiangsu Kanion Pharmaceutical Co., Ltd (SHA: 600557) and Space Peptides jointly announced the successful submission of an Investigational New Drug (IND) filing for their AI-enabled innovative drug candidate KYS2301, a chemokine receptor 8 (CCR8) peptide inhibitor. This marks the world’s first peptide inhibitor targeting CCR8 and the first peptide drug designed through AI technology to reach the IND stage.
AI-Enabled Drug Discovery
Space Peptides’ AI drug discovery platform utilizes deep learning algorithms to analyze massive compound datasets. This approach completes active molecule screening and optimization in just one-third the time required by traditional R&D methods, significantly shortening the preclinical research timeline.
Clinical Trial Plans
According to development plans, KYS2301 will undergo multicenter clinical trials in China. The primary focus will be on evaluating its efficacy and safety in patients with moderate-to-severe atopic dermatitis (AD).-Fineline Info & Tech